✦ LIBER ✦

A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpoints

✍ Scribed by Espay, A.J.; Odin, P.; Fernandez, H.H.; Hauser, R.A.; Standaert, D.G.; Lang, A.E.; Fung, V.S.; Klostermann, F.; Robieson, W.Z.; Chatamra, K.; Benesh, J.

Book ID: 123435525
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 62 KB
Volume: 333
Category: Article
ISSN: 0022-510X
DOI: 10.1016/j.jns.2013.07.426

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A long-term, open-label study of levodop

A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: Functional and health-related quality-of-life endpoints

✍ Standaert, D.G.; Fernandez, H.H.; Odin, P.; Hauser, R.A.; Espay, A.J.; Steiger, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Levodopa–carbidopa intestinal gel in adv

Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results

✍ Fernandez, Hubert H.; Vanagunas, Arvydas; Odin, Per; Espay, Alberto J.; Hauser, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 229 KB

2.254 INTERIM RESULTS FROM ONGOING, LONG

2.254 INTERIM RESULTS FROM ONGOING, LONG-TERM, OPEN-LABEL STUDY OF LEVODOPA/CARBIDOPA INTESTINAL GEL IN PATIENTS WITH PARKINSON'S DISEASE AND SEVERE MOTOR FLUCTUATIONS

✍ P. Odin; K. Chatamra; A.J. Espay; D. Standaert; H.H. Fernandez; J. Benesh; W. Ro 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Pharmacokinetics of Levodopa, Carbidopa,

Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

✍ Dag Nyholm, Per Odin, Anders Johansson, Krai Chatamra, Charles Locke… 📂 Article 📅 2012 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 261 KB

Direct switch from levodopa/benserazide

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study

✍ Karla Eggert; Örjan Skogar; Khaled Amar; Liisa Luotonen; Mikko Kuoppamäki; Mika 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 335 KB

An open-label evaluation of the tolerabi

An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off

✍ W. Koller; M. Guarnieri; J. Hubble; A. L. Rabinowicz; D. Silver 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 80 KB